Ignite Creation Date:
2025-12-24 @ 11:08 PM
Ignite Modification Date:
2026-01-05 @ 6:22 PM
Study NCT ID:
NCT04251169
Status:
TERMINATED
Last Update Posted:
2025-06-03
First Post:
2020-01-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression
Sponsor:
SOLTI Breast Cancer Research Group
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-21
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-04-30
Completion Date Type:
ACTUAL
First Submit Date:
2020-01-30
First Submit QC Date:
None
Study First Post Date:
2020-01-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-04-24
Results First Submit QC Date:
None
Results First Post Date:
2025-06-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-02
Last Update Post Date:
2025-06-03
Last Update Post Date Type:
ACTUAL